CB1 receptor inhibition restores synaptoneurosomal alternative splicing landscape in fragile X syndrome mice

Lucía de los Reyes-Ramírez, Laura Ciaran-Alfano, Marina Reixachs-Solé, Araceli Bergadà-Martínez, Lorena Galera-López, Sara Martínez-Torres +4 more

SummaryFragile X syndrome (FXS), the most frequent heritable cause of intellectual disability and autism, involves impaired cognition and synaptic plasticity. Preclinical studies show that inhibition of the cannabinoid type-1 receptor (CB1R) restores key phenotypic traits in Fmr1 knockout (FX) mice. However, the underlying molecular mechanisms remain undefined. We analyzed the hippocampal synaptoneurosomal transcr…

Editorial: Progression of diabetic kidney disease.

Mariana Charleaux de Ponte, Larissa de Araújo

Interacting binding insights and conformational consequences of the differential activity of cannabidiol with two endocannabinoid-activated G-protein-coupled receptors.

Eliud Morales Dávila, Felipe Patricio, Mariana Rebolledo-Bustillo, David Garcia-Gomez, Juan Carlos Garcia Hernandez, Brenda L. Sanchez-Gaytan +2 more

Cannabidiol (CBD), the major non-psychoactive phytocannabinoid present in the plant Cannabis sativa, has displayed beneficial pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson's disease, and Alzheimer's disease. In particular, CBD is able to modulate different receptors in the endocannabinoid system, some of which belong to the family of G-protein-coupled rec…